I’m also thinking there is a huge possibility, that no RS would even transpire, as all the new business, from a bed in a box, along with the RX purifiers revenues, coupled with the allergy free latex side. Also, Bayer testing the new inhaler. Many facets of revenues, and that not even taking Rotman’s furniture business into consideration. I think when the financials go out, and they are as good as we think, many will just in here, in a buying frenzy possibly taking the share price to multi dollars, eliminating the need for any small RS to up list to the Nasdaq.